Corcept Therapeutics | CORT - Gross Profit On Sales



Corcept Therapeutics reported $191M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.83M 19.91M Jun/2025
Alaunos Therapeutics -1127000 1.11M Sep/2024
ANI Pharmaceuticals USD 113.48M 10.61M Jun/2025
Ardelyx USD 82.84M 15.02M Jun/2025
Aurora Cannabis CAD 27.95M 18.6M Jun/2025
BioMarin Pharmaceutical USD 670.47M 76.89M Jun/2025
Bristol-Myers Squibb USD 8.9B 714M Jun/2025
Canopy Growth CAD 18.04M 6.06M Jun/2025
Corcept Therapeutics USD 191M 36.19M Jun/2025
Eli Lilly USD 13.11B 2.61B Jun/2025
J&J USD 14.6B 816M Mar/2025
Knight Therapeutics CAD 45.02M 2.32M Sep/2024
Merck USD 12.99B 224M Jun/2025
Novartis USD 11.51B 1.12B Jun/2025
Novartis USD 11.52B 1.27B Jun/2025
Pacira USD 125.91M 8.71M Jun/2025
Pfizer USD 10.88B 248M Jun/2025
Supernus Pharmaceuticals USD 127.81M 6.25M Jun/2025
TG Therapeutics USD 122.21M 16.9M Jun/2025